Erratum: Chromium supplementation and the effects on metabolic status in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial (Annals of Nutrition and Metabolism (2015) 67:1 (42-48) DOI: 10.1159/000438465);Chromium supplementation and the effects on metabolic status in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial

Annals of Nutrition and Metabolism

Volumn 67, Issue 1, 2015, Pages 42-48

  Jamilian, Mehri ^a   Asemi, Zatollah ^b  

^a ARAK UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KASHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chromium; Insulin metabolism; Lipid concentrations; Polycystic ovary syndrome; Supplementation

Indexed keywords

CHROMIUM; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; CHOLESTEROL; INSULIN; IRON CHELATING AGENT; PICOLINIC ACID; PICOLINIC ACID DERIVATIVE;

ADULT; ARTICLE; BLOOD SAMPLING; CELL FUNCTION; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; HUMAN; INSULIN BLOOD LEVEL; INSULIN METABOLISM; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; OVARY POLYCYSTIC DISEASE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; QUANTITATIVE INSULIN SENSITIVITY CHECK INDEX; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN SUPPLEMENTATION; BLOOD; DIETARY SUPPLEMENT; DOUBLE BLIND PROCEDURE; HOMEOSTASIS; INSULIN RESISTANCE; PHYSIOLOGY; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDY; YOUNG ADULT;

ADULT; CHOLESTEROL; CHOLESTEROL, VLDL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FASTING; FEMALE; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; IRON CHELATING AGENTS; PICOLINIC ACIDS; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; TRIGLYCERIDES; YOUNG ADULT;

EID: 84939541383     PISSN: 02506807     EISSN: 14219697     Source Type: Journal    
DOI: 10.1159/000529289     Document Type: Erratum

References (34)

1. Alebić MŠ, Bulum T, Stojanović N, Duvnjak L: Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria. Endocrine 2014; 47: 625-630.
2. Setji TL, Brown AJ: Polycystic ovary syndrome: update on diagnosis and treatment. Am J Med 2014; 127: 912-919.
3. Bajuk Studen K, Jensterle Sever M, Pfeifer M: Cardiovascular risk and subclinical cardiovascular disease in polycystic ovary syndrome. Front Horm Res 2013; 40: 64-82.
4. Diamanti-Kandarakis E, Dunaif A: Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012; 33: 981-1030.
5. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ: Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health - National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93: 1276-1284.
6. Ciampelli M, Leoni F, Cucinelli F, Mancuso S, Panunzi S, De Gaetano A, Lanzone A: Assessment of insulin sensitivity from measurements in the fasting state and during an oral glucose tolerance test in polycystic ovary syndrome and menopausal patients. J Clin Endocrinol Metab 2005; 90: 1398-1406.
7. Asemi Z, Esmaillzadeh A: DASH diet, insulin resistance, and serum hs-CRP in polycystic ovary syndrome: a randomized controlled clinical trial. Horm Metab Res 2015; 47: 232-238.
8. Jamilian M, Razavi M, Fakhrie Kashan Z, Ghandi Y, Bagherian T, Asemi Z: Metabolic response to selenium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf) 2015; 82: 885-891.
9. Abdollahi M, Farshchi A, Nikfar S, Seyedifar M: Effect of chromium on glucose and lipid profiles in patients with type 2 diabetes: a meta-analysis review of randomized trials. J Pharm Pharm Sci 2013; 16: 99-114.
10. Chakraborty P, Ghosh S, Goswami SK, Kabir SN, Chakravarty B, Jana K: Altered trace mineral milieu might play an aetiological role in the pathogenesis of polycystic ovary syndrome. Biol Trace Elem Res 2013; 152: 9-15.
11. Lucidi RS, Thyer AC, Easton CA, Holden AE, Schenken RS, Brzyski RG: Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicity in women with polycystic ovary syndrome. Fertil Steril 2005; 84: 1755-1757.
12. Amooee S, Parsanezhad ME, Ravanbod Shirazi M, Alborzi S, Samsami A: Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: a doubleblind randomized clinical trial. Iran J Reprod Med 2013; 11: 611-618.
13. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
14. Ramezani Tehrani F, Minooee S, Azizi F: Validation of a simplified method to assess hirsutism in the Iranian population. Eur J Obstet Gynecol Reprod Biol 2014; 174: 91-95.
15. Stein SA, Mc Nurlan M, Phillips BT, Messina C, Mynarcik D, Gelato M: Chromium therapy for insulin resistance associated with HIVdisease. J AIDS Clin Res 2013;pii:239.
16. Pisprasert V, Ingram KH, Lopez-Davila MF, Munoz AJ, Garvey WT: Limitations in the use of indices using glucose and insulin levels to predict insulin sensitivity: impact of race and gender and superiority of the indices derived from oral glucose tolerance test in African Americans. Diabetes Care 2013; 36: 845-853.
17. Bargiota A, Diamanti-Kandarakis E: The effects of old, new and emerging medicines on metabolic aberrations in PCOS. Ther Adv Endocrinol Metab 2012; 3: 27-47.
18. Martin J, Wang ZQ, Zhang XH, Wachtel D, Volaufova J, Matthews DE, Cefalu WT: Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 2006; 29: 1826-1832.
19. Ghosh D, Bhattacharya B, Mukherjee B, Manna B, Sinha M, Chowdhury J, Chowdhury S: Role of chromium supplementation in Indians with type 2 diabetes mellitus. J Nutr Biochem 2002; 13: 690-697.
20. Anderson RA, Cheng N, Bryden NA, Polansky MM, Cheng N, Chi J, Feng J: Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997; 46: 1786-1791.
21. Anderson RA, Polansky MM, Bryden NA, Canary JJ: Supplemental-chromium effects on glucose, insulin, glucagon, and urinary chromium losses in subjects consuming controlled low-chromium diets. Am J Clin Nutr 1991; 54: 909-916.
22. Masharani U, Gjerde C, McCoy S, Maddux BA, Hessler D, Goldfine ID, Youngren JF: Chromium supplementation in non-obese non-diabetic subjects is associated with a decline in insulin sensitivity. BMC Endocr Disord 2012; 12: 31.
23. Gunton JE, Cheung NW, Hitchman R, Hams G, O'Sullivan C, Foster-Powell K, McElduff A: Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance. Diabetes Care 2005; 28: 712-713.
24. Legro RS: Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003; 24: 302-312.
25. Cassar S, Teede HJ, Harrison CL, Joham AE, Moran LJ, Stepto NK: Biomarkers and insulin sensitivity in women with polycystic ovary syndrome: characteristics and predictive capacity. Clin Endocrinol (Oxf) 2015; 83: 50-58.
26. Unfer V, Porcaro G: Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome. Expert Rev Clin Pharmacol 2014; 7: 623-631.
27. Alissa EM, Bahjri SM, Ahmed WH, Al-Ama N, Ferns GA: Chromium status and glucose tolerance in Saudi men with and without coronary artery disease. Biol Trace Elem Res 2009; 131: 215-228.
28. Guallar E, Jimenez FJ, van 't Veer P, Bode P, Riemersma RA, Gomez-Aracena J, Kark JD, Arab L, Kok FJ, Martin-Moreno JM: Low toenail chromium concentration and increased risk of nonfatal myocardial infarction. Am J Epidemiol 2005; 162: 157-164.
29. Cefalu WT, Wang ZQ, Zhang XH, Baldor LC, Russell JC: Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats. J Nutr 2002; 132: 1107-1114.
30. Sharma S, Agrawal RP, Choudhary M, Jain S, Goyal S, Agarwal V: Beneficial effect of chromium supplementation on glucose, HbA1C and lipid variables in individuals with newly onset type-2 diabetes. J Trace Elem Med Biol 2011; 25: 149-153.
31. Rabinovitz H, Friedensohn A, Leibovitz A, Gabay G, Rocas C, Habot B: Effect of chromium supplementation on blood glucose and lipid levels in type 2 diabetes mellitus elderly patients. Int J Vitam Nutr Res 2004; 74: 178-182.
32. Guimaraes MM, Martins Silva Carvalho AC, Silva MS: Chromium nicotinate has no effect on insulin sensitivity, glycemic control, and lipid profile in subjects with type 2 diabetes. J Am Coll Nutr 2013; 32: 243-250.
33. Racek J, Sindberg CD, Moesgaard S, Mainz J, Fabry J, Muller L, Racova K: Effect of chromium-enriched yeast on fasting plasma glucose, glycated haemoglobin and serum lipid levels in patients with type 2 diabetes mellitus treated with insulin. Biol Trace Elem Res 2013; 155: 1-4.
34. Jain SK, Rains JL, Croad JL: Effect of chromium niacinate and chromium picolinate supplementation on lipid peroxidation, TNFalpha, IL-6, CRP, glycated hemoglobin, triglycerides, and cholesterol levels in blood of streptozotocin-treated diabetic rats. Free Radic Biol Med 2007; 43: 1124-1131.